- The FDA recently approved a new Eli Lilly drug, Zepbound (tirzepatide), for chronic weight management in adults with at least one weight-related health condition.
- Zepbound shares the same active ingredient as Mounjaro, another drug made by Eli Lilly used to treat type 2 diabetes.
- As of 2020, more than 2.6 million people globally are considered obese.
- Obesity places a person at a high risk for many serious health conditions.
According to the World Obesity Federation, more than 2.6 million people in 2020 had obesity. And that number is expected to rise to over 4 billion people by 2035.
Obesity places a person at a higher risk for serious health concerns like
Over the last year, several weight-loss drugs have become available.
Some, like Wegovy (semaglutide) have been approved by the Food and Drug Administration (FDA) for weight loss. Others like Mounjaro (tirzepatide) and Ozempic (semaglutide) are approved for helping with type 2 diabetes but are also being used off-label to assist with weight loss.
Now the FDA recently
Zepbound is an obesity treatment made by Eli Lilly and Company. They are also the makers of type 2 diabetes medication Mounjaro.
Zepbound and Mounjaro share the same active ingredient called tirzepatide.
This new weight loss drug is for adults who are obese with a body mass index (BMI) of 30 kg/m2 or greater or those who are overweight with a BMI of 27 kg/m2 or greater and who also have a weight-related medical issue.
Additionally, the medication should be used with a reduced-calorie diet and…
Read the full article here